Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma: Progress and Pitfalls

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone-refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.

Original languageEnglish (US)
Pages (from-to)2088-2090
Number of pages3
JournalCancer
Volume98
Issue number10
DOIs
StatePublished - Nov 15 2003

Fingerprint

Combination Drug Therapy
Prostate
Hormones
Carcinoma
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma : Progress and Pitfalls. / Syed, Samira.

In: Cancer, Vol. 98, No. 10, 15.11.2003, p. 2088-2090.

Research output: Contribution to journalArticle

@article{3c14fa2e1ea44d02928d539c7c313b1e,
title = "Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma: Progress and Pitfalls",
abstract = "Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone-refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.",
author = "Samira Syed",
year = "2003",
month = "11",
day = "15",
doi = "10.1002/cncr.11788",
language = "English (US)",
volume = "98",
pages = "2088--2090",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma

T2 - Progress and Pitfalls

AU - Syed, Samira

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone-refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.

AB - Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone-refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.

UR - http://www.scopus.com/inward/record.url?scp=0242611601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242611601&partnerID=8YFLogxK

U2 - 10.1002/cncr.11788

DO - 10.1002/cncr.11788

M3 - Article

C2 - 14601076

AN - SCOPUS:0242611601

VL - 98

SP - 2088

EP - 2090

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -